Wednesday, July 26, 2017
Company News: Page (1) of 1 - 02/17/17 Email this story to a friend. email article Print this page (Article printing at page facebook
New Publication Highlights DNA Damage as a Prevalent Source of Errors in Public Cancer Databases
Addressing this DNA damage could improve the detection of low-frequency disease variants, New England Biolabs® researchers report today in Science
(February 17, 2017)

IPSWICH, Mass., Feb. 17, 2017 /PRNewswire/ -- If only one in every hundred cells in a small tumor had a mutation-conferring resistance to chemotherapy, thousands of cancer cells would remain after treatment. Recently, genomics research has focused on finding these mutations in ever-smaller subpopulations of tumor cells ? or even from circulating tumor DNA in blood ? to guide treatment decisions and potentially identify new oncology therapeutics.

Unfortunately, however, detecting these genetic anomalies may be more difficult than anticipated. Routine protocols to prepare DNA for sequencing unexpectedly appear to be inducing damage in otherwise fresh, high-quality DNA samples. The resultant artifacts, due to their pattern and frequency, are confounding the detection of the "true", low-frequency mutations that are critical to understanding the genetic diversity of tumors and the drivers of recurrence in cancer patients.

A new algorithm, developed and tested by researchers at New England Biolabs (NEB®), reported today in Science, suggests this problem is widespread among DNA sequencing studies. The researchers estimated that 41 percent of the sequencing runs from the 1000 Genomes Project and 73 percent of the runs addressed in The Cancer Genome Atlas show signs of DNA damage from library preparation. More specifically, one-third or more of G-to-T mutations in reads may be false positives. Other variant calls are affected too, but less often.

"The extent of the damage in public databases surprised us. While this is very unlikely to affect the conclusions from those initiatives at the population level, these artifacts may limit the ability to assess tumor heterogeneity and the drivers of relapse in individual cancer patients. Understanding this damage offers the research community an opportunity to enhance diagnostics and accelerate cancer research," said Laurence Ettwiller, Ph.D., a research scientist at New England Biolabs and co-corresponding author on the study.

"The potential upside is that by removing these artifacts, we have the opportunity to lower the threshold for detecting bona fide somatic variants. Driver mutations among small tumor subpopulations may become much easier to identify than they have been thus far," she continued.

Most sequencing errors have been traditionally thought to result from polymerase chain reaction (PCR) mistakes, miscalls, or degraded samples ? such as formalin-fixed paraffin-embedded, ancient, or circulating tumor DNA.

"A key source of poor sequencing data quality now appears to be damage during library preparation, even for fresh DNA samples. For the next wave of genomics that is targeting increasingly low frequency mutations, success will be determined not only by maximizing library yield, but also by ensuring data quality," said Tom Evans, Ph.D., the second co-corresponding author on the study and scientific director for New England Biolabs' DNA Enzymes Division.

This research was conducted as part of a broader effort to understand the potential sources of sequencing errors and how these affect the integrity of sequencing results. Understanding these errors and their sources will permit the development of repair and workflow solutions to improve sequencing accuracy.

In the meantime, potentially problematic sequencing runs can be flagged during routine quality control using Ettwiller's open-source algorithm for estimating damage during library preparation.

Chen, L., Liu, P., Evans, T. C., & Ettwiller, L. M. DNA damage is a pervasive cause of sequencing errors, directly confounding variant identification. Science. 17 Feb 2017: Vol. 355, Issue 6326. DOI: 10.1126/science.aai8690

To view the original version on PR Newswire, visit:

SOURCE New England Biolabs

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords:England, Disease, Surgery, Science, Medical, Agricultural Science, Biology, Genetics, Cancer, Science, england, Other,
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Global Neuropsychiatric Disorders And Treatment Market Is Expected To Grow At A CAGR Of 6.2% During Forecast 2023
  • Urology Devices Global Market - Forecast to 2023
  • ChiRhoStim® (Human Secretin for Injection) FDA approved labeling update and 5-year shelf life approval
  • Wound Closure and Advanced Wound Care Global Market Forecast To 2023
  • Longeveron to Sponsor Industry Symposium on Regenerative Medicine at 2017 IAGG World Congress

  • Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration
  • Asia-Pacific Immunodiagnostics Analyzers and Reagents Market 2021: A 17-Country Analysis--Supplier Strategies, Volume and Sales Forecasts, Technology and Instrumentation Review
  • Varian to Showcase Latest Radiotherapy and Radiosurgery Technologies and Software at AAPM 2017
  • American Brain Tumor Association's Annual Patient and Family Conference to Address Physical and Cognitive Symptoms and Side Effects
  • St. Jude Children's Research Hospital®, ALSAC Announce Chairs of Boards of Directors and Governors

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines